BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

761 related articles for article (PubMed ID: 25661281)

  • 1. Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma.
    Timmer W; Moroni-Zentgraf P; Cornelissen P; Unseld A; Pizzichini E; Buhl R
    Respir Med; 2015 Mar; 109(3):329-38. PubMed ID: 25661281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study.
    Vogelberg C; Engel M; Moroni-Zentgraf P; Leonaviciute-Klimantaviciene M; Sigmund R; Downie J; Nething K; Vevere V; Vandewalker M
    Respir Med; 2014 Sep; 108(9):1268-76. PubMed ID: 25081651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma.
    Beeh KM; Moroni-Zentgraf P; Ablinger O; Hollaenderova Z; Unseld A; Engel M; Korn S
    Respir Res; 2014 Jun; 15(1):61. PubMed ID: 24890738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials.
    Kerstjens HA; Casale TB; Bleecker ER; Meltzer EO; Pizzichini E; Schmidt O; Engel M; Bour L; Verkleij CB; Moroni-Zentgraf P; Bateman ED
    Lancet Respir Med; 2015 May; 3(5):367-76. PubMed ID: 25682232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study.
    Ohta K; Ichinose M; Tohda Y; Engel M; Moroni-Zentgraf P; Kunimitsu S; Sakamoto W; Adachi M
    PLoS One; 2015; 10(4):e0124109. PubMed ID: 25894430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial.
    Paggiaro P; Halpin DM; Buhl R; Engel M; Zubek VB; Blahova Z; Moroni-Zentgraf P; Pizzichini E
    J Allergy Clin Immunol Pract; 2016; 4(1):104-13.e2. PubMed ID: 26563670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids.
    Vogelberg C; Moroni-Zentgraf P; Leonaviciute-Klimantaviciene M; Sigmund R; Hamelmann E; Engel M; Szefler S
    Respir Res; 2015 Feb; 16(1):20. PubMed ID: 25851298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysis.
    Dahl R; Engel M; Dusser D; Halpin D; Kerstjens HAM; Zaremba-Pechmann L; Moroni-Zentgraf P; Busse WW; Bateman ED
    Respir Med; 2016 Sep; 118():102-111. PubMed ID: 27578478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
    Beeh KM; Westerman J; Kirsten AM; Hébert J; Grönke L; Hamilton A; Tetzlaff K; Derom E
    Pulm Pharmacol Ther; 2015 Jun; 32():53-9. PubMed ID: 25956072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma.
    Szefler SJ; Murphy K; Harper T; Boner A; Laki I; Engel M; El Azzi G; Moroni-Zentgraf P; Finnigan H; Hamelmann E
    J Allergy Clin Immunol; 2017 Nov; 140(5):1277-1287. PubMed ID: 28189771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trial.
    Hamelmann E; Bateman ED; Vogelberg C; Szefler SJ; Vandewalker M; Moroni-Zentgraf P; Avis M; Unseld A; Engel M; Boner AL
    J Allergy Clin Immunol; 2016 Aug; 138(2):441-450.e8. PubMed ID: 26960245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial.
    Kerstjens HA; Disse B; Schröder-Babo W; Bantje TA; Gahlemann M; Sigmund R; Engel M; van Noord JA
    J Allergy Clin Immunol; 2011 Aug; 128(2):308-14. PubMed ID: 21636120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma.
    Medley H; Orozco S; Allen A
    Clin Ther; 2012 Aug; 34(8):1683-95. PubMed ID: 22796247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting β2-adrenergic agonist, in asthma; a Phase II, randomized study.
    Singh D; Pujol H; Ribera A; Seoane B; Massana E; Astbury C; Ruiz S; de Miquel G
    BMC Pulm Med; 2014 Nov; 14():176. PubMed ID: 25398689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status.
    Kerstjens HA; Moroni-Zentgraf P; Tashkin DP; Dahl R; Paggiaro P; Vandewalker M; Schmidt H; Engel M; Bateman ED
    Respir Med; 2016 Aug; 117():198-206. PubMed ID: 27492532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics and Pharmacokinetics Following Once-Daily and Twice-Daily Dosing of Tiotropium Respimat
    Beeh KM; Kirsten AM; Dusser D; Sharma A; Cornelissen P; Sigmund R; Moroni-Zentgraf P; Dahl R
    J Aerosol Med Pulm Drug Deliv; 2016 Oct; 29(5):406-415. PubMed ID: 26859538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma.
    Beeh KM; LaForce C; Gahlemann M; Wenz A; Toorawa R; Fležar M
    Respir Res; 2015 Jul; 16(1):87. PubMed ID: 26177937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tiotropium in school-age children with moderate-to-severe symptomatic asthma: A systematic review.
    Rodrigo GJ; Neffen H
    Pediatr Allergy Immunol; 2017 Sep; 28(6):573-578. PubMed ID: 28692145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of once-daily tiotropium Respimat in adults with asthma at GINA Steps 2-5.
    Buhl R; FitzGerald JM; Meltzer EO; de la Hoz A; Sigmund R; Kerstjens HAM; Bleecker ER
    Pulm Pharmacol Ther; 2020 Feb; 60():101881. PubMed ID: 31874283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease.
    Maleki-Yazdi MR; Beck E; Hamilton AL; Korducki L; Koker P; Fogarty C
    Respir Med; 2015 May; 109(5):596-605. PubMed ID: 25829298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.